Clinical trials: Diabetes Type I
Type 2 Diabetes Mellitus
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.
- Trial name
- NCT01096940
- Testing
- AZD1656, simvastatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Diabetes, Diabetes Mellitus, Type 1
Diabetes Attitudes Wishes and Needs
The study is conducted in Africa, Asia, Europe, Japan, North America and South America. The multinational surveys will explore the experiences and unmet needs of people with diabetes, as well as those of family members of people…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients
- Trial name
- DAWN2 (NCT01507116)
- Testing
- No treatment given
- Where
- 17 sites in United States, Algeria and 15 more
- Volunteers
- 8,985 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
The aim of this trial is to demonstrate bioequivalence of Wosulin R to Actrapid with regard to its total and to its maximum serum insulin concentrations.
- Trial name
- NCT00752180
- Testing
- Wosulin R, Actrapid
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wockhardt
Type 1 Diabetes Mellitus
Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
Primary Objective: To establish initial safety/tolerability and pharmacodynamic and pharmacokinetic profiles of four formulations of SAR161271 in patients with T1DM.
- Trial name
- NCT01053728
- Testing
- SAR161271, Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
The purpose of this study is to characterize the impact of acetaminophen ingestion on the performance of the Guardian™ Sensor (3) (i.e., C algorithm and Zeus algorithm) in subjects age 18 - 80 years.
- Trial name
- NCT04378114
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data., Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data., Acetominophen
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated haemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 diabetes mellitus (T1DM) also using insulin glargine.
- Trial name
- SORELLA1 (NCT02273180)
- Testing
- SAR342434, Humalog, Insulin glargine HOE901
- Where
- 89 sites in United States, France and 6 more
- Volunteers
- 507 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
- Trial name
- NCT01110746
- Testing
- Viaject 7, LISPRO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biodel
Type 1 Diabetes Mellitus
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years.
- Trial name
- NCT02239354
- Testing
- VC-01™ Combination Product
- Where
- 2 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- ViaCyte
Type 1 Diabetes
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Primary objective To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
- Trial name
- CONSERVA (NCT05368402)
- Testing
- Ladarixin
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes
A Performance Evaluation of the Enlite 3 Sensor
The purpose of this study is to support the use of the Enlite 3 sensor in arm and thigh in subjects age 14 - 75 years and provide additional characterization of the Enlite 3 sensor performance in arm in subjects age 14 - 75 years.
- Trial name
- NCT02649010
- Testing
- Enlite 3 Sensor
- Where
- 2 sites in United States
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Amidst medical innovations, many Type 1 diabetes patients using advanced therapy show improved control but still suffer from diabetes-related distress.
- Trial name
- PRO-DIAB-1 (NCT06050642)
- Testing
- enhanced care model provided by Timkl, a home support provider
- Where
- France
- Volunteers
- 340 people
- Sponsor
- timkl
Type 1 Diabetes
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting.
- Trial name
- NCT02748018
- Testing
- 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
- Where
- 36 sites in United States, Canada and 7 more
- Volunteers
- 959 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00675493
- Testing
- biphasic insulin aspart 30
- Where
- Romania
- Volunteers
- 942 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety While Using Levemir®
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions in Egypt.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00701155
- Testing
- insulin detemir
- Where
- Egypt
- Volunteers
- 3,593 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02230618
- Testing
- insulin degludec/insulin aspart
- Where
- 35 sites in India
- Volunteers
- 1,029 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.